Cervilenz Inc. to Present at the Premier MedTech Conference – AdvaMed 2011

CLEVELAND, OH – September 26, 2011

Cervilenz Inc. will be presenting this year at AdvaMed 2011 in Washington, DC. to share news on a significant advance in obstetrics and how their new device will help physicians improve pregnancy outcomes. The presentation is on Wednesday, September 28, 2011 at 11:40 am at the Walter E. Washington Convention Center.

CerviLenz® is an innovative medical device that measures cervical length to help identify and manage pregnant women at high risk of preterm birth. Preterm birth affects over 12% of pregnancies and is the leading cause of infant morbidity and mortality. Over 545,000 infants are born prematurely each year in the United States, with an annual economic toll of $26.2 billion dollars.

“Cervilenz Inc. was founded anticipating a milestone in obstetrics: an evidence-based preventive therapy for preterm birth for women with a short cervix,” said Dean Koch, President and CEO. “This preventive therapy is finally on the horizon, and CerviLenz is poised to play a vital role in dramatically reducing the number of preterm births worldwide.”

Prediction is the key to prevention. For many years, researchers and clinicians have known that the best way to predict preterm birth is cervical length measurement. Pregnant women with a short cervix mid-gestation are 6 times more likely to deliver preterm. A recently published study conducted by the National Institutes of Health demonstrated a 45% reduction in preterm birth for women with a short cervix treated with a vaginal progesterone gel, Prochieve® 8%. This treatment was also proven to significantly improve neonatal outcomes. Given these results, experts are now calling for a fundamental change in obstetric care to include routine cervical length measurements for all pregnant women.

CerviLenz allows immediate, reliable cervical length measurement during regular prenatal visits, empowering physicians to evaluate all of their patients for preterm birth risk multiple times during their pregnancy.

CerviLenz is covered by U.S. and international patents. CerviLenz is cleared for sale in the U.S. and just received its CE mark approval.

About Cervilenz Inc.
Cervilenz Inc. manufactures and markets CerviLenz® – an innovative medical device that measures cervical length to help identify and manage pregnant women at high risk for preterm birth. Dedicated to making a difference in the world of prematurity, Cervilenz Inc. donates a portion of revenue to charitable organizations that advance maternal and fetal health globally. Founded in 2008, the company headquarters is in Chagrin Falls, a suburb of Cleveland, Ohio. CerviLenz was designed and is manufactured in Ohio. For more information, please visit cervilenz.com on contact Melanie Sweeney, Director of Marketing (440.337.4253 or melanie@cervilenz.com).

About AdvaMed 2011
AdvaMed 2011 is the premier MedTech Conference for CEOs, business executives, policy-makers, financiers, media, and industry stakeholders from around the world. AdvaMed 2011 is the only place in North America where you can network with more than 1,500 key MedTech executives from companies in every sector of the industry. This event brings together policy-makers, experts, and insiders for critical dialogues on subjects ranging from regulatory affairs and reimbursement to IP and business development. For more information, visit AdvaMed2011.com.

Cervilenz Inc.
100 N. Main Street, Suite 300
Chagrin Falls, OH 44022
Melanie Sweeney
melanie@cervilenz.com

This release was published on openPR.